Effect of autologous NK cell immunotherapy on advanced lung adenocarcinoma with EGFR mutations

IF 5.1 4区 医学 Q1 MEDICINE, RESEARCH & EXPERIMENTAL
Guodai Hong, Xuemei Chen, Xizhuo Sun, Meiling Zhou, Bing Liu, Zhu Li, Zhen-dong Yu, Wenbin Gao, Tao Liu
{"title":"Effect of autologous NK cell immunotherapy on advanced lung adenocarcinoma with EGFR mutations","authors":"Guodai Hong, Xuemei Chen, Xizhuo Sun, Meiling Zhou, Bing Liu, Zhu Li, Zhen-dong Yu, Wenbin Gao, Tao Liu","doi":"10.1093/pcmedi/pbz023","DOIUrl":null,"url":null,"abstract":"Abstract This study investigated the efficiency of natural killer (NK) cell immunotherapy on non-small cell lung cancer with and without EGFR mutations in order to evaluate the response rate (RR) and progression-free survival (PFS). Among the 48 patients recruited, 24 were clinically confirmed to be EGFR mutation positive. The study group was treated with autologous NK cell immunotherapy. Comparisons of the lymphocyte number, serum tumour-related biomarkers, circulating tumour cells (CTC), Karnofsky Performance Status (KPS) and survival curves were carried out before and after NK cell immunotherapy. The safety and short-term effects were evaluated, followed by median PFS and RR assessments. The serum CEA and CA125 values were found lower in the NK cell therapy group than that of the non-NK treatment group (p < 0.05). The χ2 test showed a 75% RR of the study group A, significantly higher than that of the control group B (16.7%; p < 0.01). The RR of groups C (58.3%) and D (41.7%) were not statistically significant. The p values of the 4 groups were 0.012, 0.012, 0.166 and 1 from group A to group D, respectively. The median PFS was 9 months in EGFR mutation positive group undergoing NK cell infusion interference. By evaluating the changes in immune function, tumour biomarkers, CTC, KPS and PFS, we demonstrated that NK cell therapy had better clinical therapeutic effects on EGFR mutation-positive lung adenocarcinoma.","PeriodicalId":33608,"journal":{"name":"Precision Clinical Medicine","volume":"27 1","pages":"235 - 245"},"PeriodicalIF":5.1000,"publicationDate":"2019-11-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"6","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Precision Clinical Medicine","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1093/pcmedi/pbz023","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"MEDICINE, RESEARCH & EXPERIMENTAL","Score":null,"Total":0}
引用次数: 6

Abstract

Abstract This study investigated the efficiency of natural killer (NK) cell immunotherapy on non-small cell lung cancer with and without EGFR mutations in order to evaluate the response rate (RR) and progression-free survival (PFS). Among the 48 patients recruited, 24 were clinically confirmed to be EGFR mutation positive. The study group was treated with autologous NK cell immunotherapy. Comparisons of the lymphocyte number, serum tumour-related biomarkers, circulating tumour cells (CTC), Karnofsky Performance Status (KPS) and survival curves were carried out before and after NK cell immunotherapy. The safety and short-term effects were evaluated, followed by median PFS and RR assessments. The serum CEA and CA125 values were found lower in the NK cell therapy group than that of the non-NK treatment group (p < 0.05). The χ2 test showed a 75% RR of the study group A, significantly higher than that of the control group B (16.7%; p < 0.01). The RR of groups C (58.3%) and D (41.7%) were not statistically significant. The p values of the 4 groups were 0.012, 0.012, 0.166 and 1 from group A to group D, respectively. The median PFS was 9 months in EGFR mutation positive group undergoing NK cell infusion interference. By evaluating the changes in immune function, tumour biomarkers, CTC, KPS and PFS, we demonstrated that NK cell therapy had better clinical therapeutic effects on EGFR mutation-positive lung adenocarcinoma.
自体NK细胞免疫治疗晚期EGFR突变肺腺癌的疗效观察
摘要本研究旨在探讨自然杀伤细胞(NK)免疫治疗对EGFR突变和非EGFR突变的非小细胞肺癌的疗效,以评估其缓解率(RR)和无进展生存期(PFS)。在纳入的48例患者中,24例临床证实为EGFR突变阳性。实验组采用自体NK细胞免疫治疗。比较NK细胞免疫治疗前后淋巴细胞数量、血清肿瘤相关生物标志物、循环肿瘤细胞(CTC)、Karnofsky Performance Status (KPS)和生存曲线。评估安全性和短期效果,然后评估中位PFS和RR。NK细胞治疗组血清CEA、CA125值明显低于非NK细胞治疗组(p < 0.05)。χ2检验显示,a研究组的RR为75%,显著高于对照组B组(16.7%;P < 0.01)。C组(58.3%)、D组(41.7%)的RR差异无统计学意义。A组与D组的p值分别为0.012、0.012、0.166和1。EGFR突变阳性组接受NK细胞输注干扰,中位PFS为9个月。通过免疫功能、肿瘤生物标志物、CTC、KPS和PFS的变化,我们证明NK细胞治疗对EGFR突变阳性肺腺癌有更好的临床治疗效果。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Precision Clinical Medicine
Precision Clinical Medicine MEDICINE, RESEARCH & EXPERIMENTAL-
CiteScore
10.80
自引率
0.00%
发文量
26
审稿时长
5 weeks
期刊介绍: Precision Clinical Medicine (PCM) is an international, peer-reviewed, open access journal that provides timely publication of original research articles, case reports, reviews, editorials, and perspectives across the spectrum of precision medicine. The journal's mission is to deliver new theories, methods, and evidence that enhance disease diagnosis, treatment, prevention, and prognosis, thereby establishing a vital communication platform for clinicians and researchers that has the potential to transform medical practice. PCM encompasses all facets of precision medicine, which involves personalized approaches to diagnosis, treatment, and prevention, tailored to individual patients or patient subgroups based on their unique genetic, phenotypic, or psychosocial profiles. The clinical conditions addressed by the journal include a wide range of areas such as cancer, infectious diseases, inherited diseases, complex diseases, and rare diseases.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信